Iovance Biotherapeutics Class Action Lawsuit
Analysis based on 14 articles · First reported May 21, 2025 · Last updated Jun 09, 2025
The market is impacted by the significant decline in Atara Biotherapeutics' stock price due to alleged misleading statements and reduced revenue guidance. This event highlights the risks associated with investing in companies that may not accurately represent their growth potential, potentially leading to investor losses and legal actions.
Atara Biotherapeutics is facing a class action lawsuit initiated by The Gross Law Firm on behalf of shareholders who purchased shares between May 9, 2024, and May 8, 2025. The lawsuit alleges that Atara Biotherapeutics made overwhelmingly positive but materially false and misleading statements regarding its growth potential and ability to capitalize on demand for its treatments. This came to light on July 25, 2024, when Atara Biotherapeutics announced its Q2 2024 financial results and significantly reduced its revenue guidance for the full fiscal year, attributing it to scheduled maintenance, lower Proleukin sales, and a variable pace of patient treatment. Following this announcement, Atara Biotherapeutics' stock price dramatically fell by approximately 44.795% in a single day, from $3.17 to $1.75 per share. The deadline for shareholders to seek lead plaintiff appointment is July 14, 2025.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard